Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $22.6300 (-2.23%) ($22.6300 - $22.6300) on Tue. Dec. 29, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.97% (three month average) | RSI | 54 | Latest Price | $22.6300(-2.23%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.4% a day on average for past five trading days. | Weekly Trend | FOLD advances 2.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(50%) XBI(48%) IWM(47%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -1.485% in a week (0% probabilities). VIXM(-29%) VXX(-13%) UUP(-11%) UNG(-6%) TLT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.485% (StdDev 2.97%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Resistance Level | $23.32 | 5 Day Moving Average | $23.84(-5.08%) | 10 Day Moving Average | $23.9(-5.31%) | 20 Day Moving Average | $23.32(-2.96%) | To recent high | -9.2% | To recent low | 67.9% | Market Cap | $5.844b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |